SR3.F STAAR Surgical Company

Healthcare Health Care Equipment & Supplies Frankfurt Exchange
24.07 EUR
Close of Nov 12, 2026
13.51 29.00
Market cap
EUR 1.21B
P/E
2,407.0x
P/B
3.19x
ROE
6.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SR3.F undervalued?

Graham number

The Graham number of STAAR Surgical Company cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

STAAR Surgical Company fundamental analysis

No fundamental analysis for STAAR Surgical Company yet.

STAAR Surgical Company stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health car…

Full company profile